Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Nature·2026
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

<i>SMARCA4, STK11,</i> and <i>KEAP1</i> co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.

bioRxiv : the preprint server for biology·2026
Same author

Clinicogenomic analysis of <i>EGFR</i>-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

Science translational medicine·2026
Same author

State-of-the-Art Mediastinal Staging in Non-Small-Cell Lung Cancer: Integration of Combined Endosonographic Techniques with Updated IASLC TNM 9th Classification.

Cancers·2026

相关实验视频

Updated: Feb 28, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

基于CT扫描的多机构放射学,用于预测晚期和有限非小细胞肺癌患者的瘤PD-L1表达.

Ralph Saber1,2, Marion Tonneau2,3, Olivier Salko2

  • 1MedICAL Laboratory, Polytechnique Montreal, Montreal, QC H3T 1J4, Canada.

Cancers
|February 27, 2026
PubMed
概括
此摘要是机器生成的。

一种使用CT扫描的新型放射学算法可以预测非小细胞肺癌 (NSCLC) 中的编程死亡配体1 (PD-L1) 表达. 这种非侵入性方法显示为免疫检查点抑制剂 (ICI) 治疗的生物标志物具有前景,可能改善患者的治疗结果.

关键词:
免疫检查点封锁封锁非小细胞肺癌的肺癌.非侵入性的生物标志物.编程死亡链条 1 编程死亡链条 1无线电学 (radiomics) 是一种无线电学.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K
Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
07:53

Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer

Published on: October 13, 2023

2.2K

相关实验视频

Last Updated: Feb 28, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K
Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
07:53

Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer

Published on: October 13, 2023

2.2K

科学领域:

  • 在瘤学瘤学.
  • 放射学 放射学是一门学科.
  • 人工智能的人工智能

背景情况:

  • 免疫检查点抑制剂 (ICI) 已经改变了高级非小细胞肺癌 (NSCLC) 治疗.
  • 然而,70%的患者经历疾病进展,需要预测生物标志物.
  • 编程死亡连接体1 (PD-L1) 表达是一种关键的生物标志物,但其评估是侵入性的.

研究的目的:

  • 使用计算机断层扫描 (CT) 成像开发PD-L1表达 (rad-PDL1) 的非侵入性放射性替代物.
  • 将rad-PDL1的预测值与传统的病理学评估进行比较.
  • 评估rad-PDL1在先进阶段和有限阶段NSCLC中的通用性.

主要方法:

  • 来自预处理CT扫描的放射特征使用基于变压器模型的管道进行分析.
  • 算法将瘤分类为高与低的PD-L1表达.
  • 在482名晚期NSCLC患者和51名有限期NSCLC患者的独立队列中进行了验证.

主要成果:

  • 放射学管道在初级和独立验证中表现出强大的预测性能,AUC分别为0.75和0.68.
  • 精度为0.73和0.69,表明在疾病阶段具有良好的概括性.
  • 较高的rad-PDL1表达与较长的无进展生存时间相关.

结论:

  • 基于CT的PD-L1表达的放射性替代物是可行的.
  • 该方法显示了对独立的新辅助体队伍的部分概括.
  • 在临床实施之前,需要进行更大的前性,多站点验证.